Pharsight

Janssen Biotech patents expiration

1. Akeega patents expiration

AKEEGA's oppositions filed in EPO
AKEEGA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436185 JANSSEN BIOTECH Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(4 years from now)

US8071623 JANSSEN BIOTECH Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(6 years from now)

US11673877 JANSSEN BIOTECH Niraparib compositions
Mar, 2038

(13 years from now)

US11091459 JANSSEN BIOTECH Niraparib compositions
Mar, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143241 JANSSEN BIOTECH DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(3 years from now)

US8071579 JANSSEN BIOTECH DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(3 years from now)

US8859562 JANSSEN BIOTECH Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(7 years from now)

US11207311 JANSSEN BIOTECH Method of treating prostate cancer
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

More Information on Dosage

AKEEGA family patents

Family Patents

2. Balversa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2031

(6 years from now)

US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators
Mar, 2035

(10 years from now)

US11684620 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(11 years from now)

US10898482 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(11 years from now)

US11077106 JANSSEN BIOTECH Cancer treatment
Feb, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 12, 2024
New Indication(I-930) Jan 19, 2027

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 13 April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...

Dosage: TABLET;ORAL

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Erleada patents expiration

ERLEADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9388159 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(2 years from now)

US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(6 years from now)

US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987261 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(2 years from now)

US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Mar, 2027

(2 years from now)

US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(9 years from now)

US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(9 years from now)

USRE49353 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(9 years from now)

US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(9 years from now)

US10702508 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Apr, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-808) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 14 February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment of non-metas...

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

4. Zytiga patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5604213 JANSSEN BIOTECH 17-substituted steroids useful in cancer treatment
Feb, 2014

(10 years ago)

US8822438 JANSSEN BIOTECH Methods and compositions for treating cancer
Aug, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-765) Feb 07, 2021
New Indication(I-663) Dec 10, 2015
New Chemical Entity Exclusivity(NCE) Apr 28, 2016

Drugs and Companies using ABIRATERONE ACETATE ingredient

NCE-1 date: 29 April, 2015

Market Authorisation Date: 28 April, 2011

Treatment: Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel; Use in combination with...

Dosage: TABLET;ORAL

How can I launch a generic of ZYTIGA before it's drug patent expiration?
More Information on Dosage

ZYTIGA family patents

Family Patents